Accelerated Approval Granted to Beqalzi (Sonrotoclax) for Mantle Cell Lymphoma by Madaline Spencer| Published on: May 15, 2026

https://checkrare.com/accelerated-approval-granted-to-beqalzi-sonrotoclax-for-mantle-cell-lymphoma/ The US Food and Drug Administration (FDA) has granted accelerated approval to Beqalzi (sonrotoclax) for the treatment of adults with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.